Treatment of Relapsed/Refractory Ph+ ALL

CME: 0.5

July 25, 2022
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

The target audience for this initiative includes hematology/oncology physicians and other members of the multidisciplinary cancer care team involved in the management of patients with acute lymphocytic leukemia.

Program Overview

This activity is the second in a series of four educational activities focusing on the treatment of relapsed/refractory ALL. Dr. Jessica Leonard, from Oregon Health and Science University, discusses diagnoses and treatment options, and will walk through a case study of a patient with Ph+ ALL.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who could benefit from CD22-directed ADC therapy using current practice guideline recommendations
  • Develop strategies to prevent, monitor, and manage VOD associated with CD22-directed ADC therapy

Post a comment to this article